MannKind earns FDA nod for on-body infusor, new autoinjector patents
December 23, 2025
MannKind (Nasdaq:MNKD) announced today that the FDA approved its Furoscix (furosemide) on-body infusor for pediatric patients.
MannKind (Nasdaq:MNKD) announced today that the FDA approved its Furoscix (furosemide) on-body infusor for pediatric patients.
A new method could enable users to design portable medical devices, like a splint, that can be rapidly converted from flat panels to a 3D object without any tools.
Edwards Lifesciences (NYSE: EW)+
has won FDA approval for its Sapien M3 mitral valve replacement system for treating mitral regurgitation (MR).